Trial results

$TTRX — GX-03

Turn Therapeutics Inc. (TTRX) GX-03: trial results in Moderate-to-severe atopic dermatitis, 2027.

Research by Catalyst Intel

The catalyst

"Phase 2 RCT trial underway for moderate to severe AD, topline results expected Q1 2027"

— Turn Therapeutics, 8-K filed 2026-10-07 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

TTRX-GX03-2026

Company

Turn Therapeutics Inc.

Kind

Trial results

Indication

Moderate-to-severe atopic dermatitis

Window

2027-01-01 – 2027-03-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-04-30; subscribers get it on the day.